SG11201401032YA - (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators - Google Patents
(4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulatorsInfo
- Publication number
- SG11201401032YA SG11201401032YA SG11201401032YA SG11201401032YA SG11201401032YA SG 11201401032Y A SG11201401032Y A SG 11201401032YA SG 11201401032Y A SG11201401032Y A SG 11201401032YA SG 11201401032Y A SG11201401032Y A SG 11201401032YA SG 11201401032Y A SG11201401032Y A SG 11201401032YA
- Authority
- SG
- Singapore
- Prior art keywords
- phenylimidazol
- sodium channel
- derivatives useful
- channel modulators
- ethylamine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161551628P | 2011-10-26 | 2011-10-26 | |
PCT/IB2012/055610 WO2013061205A2 (en) | 2011-10-26 | 2012-10-15 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201401032YA true SG11201401032YA (en) | 2014-07-30 |
Family
ID=47278356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201401032YA SG11201401032YA (en) | 2011-10-26 | 2012-10-15 | (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators |
Country Status (28)
Country | Link |
---|---|
US (1) | US9079878B2 (en) |
EP (1) | EP2771335A2 (en) |
JP (1) | JP5946538B2 (en) |
KR (1) | KR101586966B1 (en) |
CN (1) | CN103906746B (en) |
AP (1) | AP2014007579A0 (en) |
AU (1) | AU2012328034B2 (en) |
BR (1) | BR112014009102A2 (en) |
CA (1) | CA2850925C (en) |
CL (1) | CL2014000956A1 (en) |
CO (1) | CO6940427A2 (en) |
CR (1) | CR20140185A (en) |
CU (1) | CU20140046A7 (en) |
DO (1) | DOP2014000085A (en) |
EA (1) | EA023375B1 (en) |
EC (1) | ECSP14013324A (en) |
GT (1) | GT201400079A (en) |
HK (1) | HK1198650A1 (en) |
IL (1) | IL232267A (en) |
MD (1) | MD20140037A2 (en) |
MX (1) | MX337469B (en) |
NI (1) | NI201400031A (en) |
PE (1) | PE20141682A1 (en) |
SG (1) | SG11201401032YA (en) |
TN (1) | TN2014000147A1 (en) |
UA (1) | UA109220C2 (en) |
WO (1) | WO2013061205A2 (en) |
ZA (1) | ZA201402281B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103827124B (en) * | 2011-09-14 | 2017-06-06 | 陶氏益农公司 | Method and system for forming boric acid class and its intermediate |
GEP20217223B (en) | 2013-12-13 | 2021-02-10 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
KR102192572B1 (en) | 2014-06-09 | 2020-12-18 | 삼성전자주식회사 | Method of manufacturing light source module |
EP3209303A1 (en) | 2014-10-24 | 2017-08-30 | Avectas Limited | Delivery across cell plasma membranes |
KR20170117170A (en) | 2015-02-19 | 2017-10-20 | 퍼듀 퍼머 엘피 | Methods and compositions for reducing gastric emptying |
IS2977B (en) | 2015-02-23 | 2017-07-15 | Actavis Group Ptc Ehf. | Process for the preparation of intermediates useful in the synthesis of eluxadoline |
CN109312315B (en) | 2015-12-30 | 2023-06-09 | 阿维塔斯有限公司 | Carrier-free delivery of gene-editing proteins and compositions to cells and tissues |
AU2017292169B2 (en) * | 2016-07-06 | 2021-12-23 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
JP2019520079A (en) | 2016-07-06 | 2019-07-18 | クリスパー セラピューティクス アクチェンゲゼルシャフト | Substances and methods for treating pain related disorders |
CA3063901A1 (en) | 2017-05-16 | 2018-11-22 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
TW201920081A (en) | 2017-07-11 | 2019-06-01 | 美商維泰克斯製藥公司 | Carboxamides as modulators of sodium channels |
CN111918650A (en) | 2018-02-12 | 2020-11-10 | 沃泰克斯药物股份有限公司 | Method of treating pain |
WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
US20230062053A1 (en) | 2019-01-10 | 2023-03-02 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
CA3164134A1 (en) | 2019-12-06 | 2021-06-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
EP4347032A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
AU2022286511A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
AU2022286438A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
UY39800A (en) | 2021-06-04 | 2023-01-31 | Vertex Pharma | N–(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS SODIUM CHANNEL MODULATORS |
AU2022285758A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
KR20240031299A (en) | 2021-06-04 | 2024-03-07 | 버텍스 파마슈티칼스 인코포레이티드 | (2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran Solid dosage forms and dosing regimens comprising -2-carbonyl]amino]pyridine-2-carboxamide |
WO2023205778A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
US20230373925A1 (en) | 2022-04-22 | 2023-11-23 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023211990A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (en) | 1990-01-23 | 1999-01-15 | . | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US7291641B2 (en) * | 1999-10-11 | 2007-11-06 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
TWI292316B (en) * | 1999-10-11 | 2008-01-11 | Sod Conseils Rech Applic | Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof |
US7112366B2 (en) | 2001-01-05 | 2006-09-26 | The Ohio State University | Chemical monolayer and micro-electronic junctions and devices containing same |
TWI248438B (en) * | 2001-04-10 | 2006-02-01 | Sod Conseils Rech Applic | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
FR2842808B1 (en) * | 2002-07-25 | 2004-09-10 | Sod Conseils Rech Applic | NOVEL ARYLIMIDAZOLA DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS |
US7456164B2 (en) * | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
PT1747210E (en) * | 2004-05-07 | 2010-08-31 | Warner Lambert Co | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands |
US7786291B2 (en) | 2004-10-27 | 2010-08-31 | Schering Corporation | Compositions and methods for short interfering nucleic acid inhibition of Nav1.8 |
RS54522B1 (en) | 2005-12-22 | 2016-06-30 | Newron Pharmaceuticals S.P.A. | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators |
AP2780A (en) | 2006-10-18 | 2013-09-30 | Pfizer Prod Inc | Biaryl ether urea compounds |
EP1995241B1 (en) | 2007-03-23 | 2010-03-17 | ICAgen, Inc. | Inhibitors of ion channels |
JP2010526051A (en) * | 2007-05-03 | 2010-07-29 | ファイザー・リミテッド | N- [6-amino-5- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as NAV1.8 channel modulators for the treatment of pain |
MX2009011816A (en) | 2007-05-03 | 2009-11-19 | Pfizer Ltd | 2 -pyridine carboxamide derivatives as sodium channel modulators. |
CA2693588C (en) | 2007-07-13 | 2015-11-17 | Icagen, Inc. | Sodium channel inhibitors |
-
2012
- 2012-10-15 MX MX2014004738A patent/MX337469B/en active IP Right Grant
- 2012-10-15 PE PE2014000605A patent/PE20141682A1/en not_active Application Discontinuation
- 2012-10-15 MD MDA20140037A patent/MD20140037A2/en not_active Application Discontinuation
- 2012-10-15 EA EA201490864A patent/EA023375B1/en not_active IP Right Cessation
- 2012-10-15 WO PCT/IB2012/055610 patent/WO2013061205A2/en active Application Filing
- 2012-10-15 JP JP2014537760A patent/JP5946538B2/en not_active Expired - Fee Related
- 2012-10-15 AU AU2012328034A patent/AU2012328034B2/en not_active Ceased
- 2012-10-15 AP AP2014007579A patent/AP2014007579A0/en unknown
- 2012-10-15 BR BR112014009102A patent/BR112014009102A2/en active Search and Examination
- 2012-10-15 EP EP12794777.8A patent/EP2771335A2/en not_active Withdrawn
- 2012-10-15 CN CN201280052591.6A patent/CN103906746B/en not_active Expired - Fee Related
- 2012-10-15 UA UAA201404440A patent/UA109220C2/en unknown
- 2012-10-15 SG SG11201401032YA patent/SG11201401032YA/en unknown
- 2012-10-15 KR KR1020147010826A patent/KR101586966B1/en not_active IP Right Cessation
- 2012-10-15 CA CA2850925A patent/CA2850925C/en not_active Expired - Fee Related
- 2012-10-15 US US14/351,893 patent/US9079878B2/en not_active Expired - Fee Related
-
2014
- 2014-03-27 ZA ZA2014/02281A patent/ZA201402281B/en unknown
- 2014-04-08 TN TNP2014000147A patent/TN2014000147A1/en unknown
- 2014-04-14 CL CL2014000956A patent/CL2014000956A1/en unknown
- 2014-04-23 NI NI201400031A patent/NI201400031A/en unknown
- 2014-04-24 CR CR20140185A patent/CR20140185A/en unknown
- 2014-04-24 CU CU2014000046A patent/CU20140046A7/en unknown
- 2014-04-25 GT GT201400079A patent/GT201400079A/en unknown
- 2014-04-25 EC ECSP14013324 patent/ECSP14013324A/en unknown
- 2014-04-25 DO DO2014000085A patent/DOP2014000085A/en unknown
- 2014-04-27 IL IL232267A patent/IL232267A/en not_active IP Right Cessation
- 2014-04-28 CO CO14090473A patent/CO6940427A2/en active IP Right Grant
- 2014-12-03 HK HK14112181.8A patent/HK1198650A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1198650A1 (en) | (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators (4--2-) | |
HK1238627A1 (en) | Fused heterocyclic compounds as sodium channel modulators | |
HK1200713A1 (en) | Benzyl sulfonamide derivatives as rorc modulators rorc | |
SI2581991T1 (en) | Holder frame for connector | |
HK1201526A1 (en) | Benzyl sulfonamide derivatives as rorc modulators rorc | |
PT2663550T (en) | Substituted benzoazepines as toll-like receptor modulators | |
EP2663555A4 (en) | Substituted benzoazepines as toll-like receptor modulators | |
EP2794880A4 (en) | Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression | |
EP2709985A4 (en) | Amine derivatives as potassium channel blockers | |
EP2568021B8 (en) | Ink Composition | |
EP2661179A4 (en) | Reduced sodium composition | |
EP2676553A4 (en) | Carotenoid-containing composition | |
HK1190884A1 (en) | Carotenoid coloring composition | |
EP2659313A4 (en) | Printing | |
HK1179956A1 (en) | Fused heterocycic derivatives as s1p modulators s1p | |
IL233001A0 (en) | Novel iso-ergoline derivatives | |
EP2688426A4 (en) | Reduced sodium salt composition | |
HK1196605A1 (en) | 2-oxo-piperidinyl derivatives 2-- | |
AU2012902375A0 (en) | Low sodium salt | |
AU2011903092A0 (en) | Improvements Relating To Printing | |
GB201106990D0 (en) | Connector for frames | |
GB201101084D0 (en) | Connector for frames | |
GB201220680D0 (en) | Antibacterials | |
AU2011903834A0 (en) | Alignment Apparatus | |
AU2011903178A0 (en) | 888-SuperPower (KineticEnergy2ElectricPower) |